UNSPSC 51313442: Triprolidine hydrochloride monohydrate

This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H22N2.ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YAN7R5L890, chemically known as (e)-2-(3-(1-pyrrolidinyl)-1-p-tolylpropenyl)pyridine monohydrochloride monohydrate, but more generally known as triprolidine hydrochloride monohydrate, which bears US NIH Compound Identifier 6433473.

European Medicines Agency schedules triprolidine hydrochloride monohydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11323MIG. Most nations, for tariff purposes, schedule triprolidine hydrochloride monohydrate under HS 29333999. SMILES: CC1CCC(CC1)/C(=C\CN2CCCC2)/C3CCCCN3.O.CL.

UNSPSC 51313442 Triprolidine hydrochloride monohydrate is a Commodity code that in recent state and local procurement activity does not align with what is actually being solicited. The recent opportunities tagged to this code — naloxone procurement, direct-to-manufacturer pharmacy programs, and generic multi-source pharmaceutical contracting — do not involve triprolidine hydrochloride monohydrate as a product line. The code shows little relevant recent activity; the mismatch between the code's nominal chemical-specific scope and the broader pharmaceutical and OTC procurement being solicited suggests either tagging error or that triprolidine monohydrate does not drive standalone state and local demand at this time.

The three recent opportunities span issuing bodies including Seminole County, Florida (health operations), the Texas Health and Human Services Commission (state pharmacy benefit), and the Minnesota Multistate Cooperative Purchasing Alliance serving state and local facilities across multiple states including Oregon. The Seminole County IFB S1070000015802, posted June 30, 2026, solicits naloxone and drug deactivation systems with a response deadline of July 26, 2023; the Texas HHS RFI HHS0017013, posted April 3, 2026, gathers vendor intelligence on direct-to-manufacturer prescription programs; and the MMCAP RFP, posted January 20, 2026, with a March 26, 2026 response deadline, establishes contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers nationwide. These opportunities reflect state and local interest in pharmaceutical supply chain efficiency, naloxone access, and manufacturer-direct relationships rather than triprolidine-specific procurement.